Blueprint for Transparency at the U.S. Food and Drug Administration: Recommendations to Advance the Development of Safe and Effective Medical Products
Sharfstein J, Miller J, Davis A, Ross J, McCarthy M, Smith B, Chaudhry A, Alexander G, Kesselheim A. Blueprint for Transparency at the U.S. Food and Drug Administration: Recommendations to Advance the Development of Safe and Effective Medical Products. The Journal Of Law, Medicine & Ethics 2017, 45: 7-23. DOI: 10.1177/1073110517750615.Commentaries, Editorials and LettersYale Law SchoolEffective medical productsSuch medical productsMedical productsJohn Arnold FoundationLaw schoolsCongressional authorizationDevelopment of SafeYale Medical SchoolFDA practiceCongressional actionRegulatory statusRegulatory processesTransparencyPolicy constraintsJohns Hopkins Bloomberg SchoolPractical recommendationsPublicPublic healthTask ForceSpecific recommendationsRecommendationsPracticeBlueprintAuthorization